Semaglutide (brand names Ozempic and Wegovy) has taken the medical world by storm. These drugs belong to a class called GLP-1 receptor agonists, which mimic a natural hormone known as glucagon-like peptide-1. 

Most people know semaglutide for its effects on weight and blood sugar. It works in several places in the body: the gut, where it slows the movement of food; the brain, where it reduces appetite and cravings; and the pancreas, where it helps trigger insulin release when blood sugar rises. 

But researchers are increasingly noticing something else: semaglutide appears to reduce inflammation. 

A 2024 review titled “Anti-Inflammatory Benefits of Semaglutide: State of the Art” summarized growing evidence that GLP-1 drugs suppress key inflammatory markers such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). These molecules are part of the body’s inflammatory signaling system and are elevated in many chronic diseases.  

This anti-inflammatory action likely contributes to semaglutide’s benefits in cardiovascular and kidney disease in patients with diabetes. Interestingly, some studies suggest that these effects may occur independently of blood sugar control, raising the possibility that semaglutide might help conditions driven by inflammation. 

That has led researchers to explore potential roles in disorders such as: 

One intriguing example appeared in a recent case report in the journal Cureus describing a woman with severe dysmenorrhea (menstrual pain). Treatment with semaglutide significantly improved her symptoms. 

What makes that report especially interesting is the dose used. 

Rather than standard weight-loss dosing, the physicians used a very small amount of semaglutide—below what many clinics would consider a starting dose. This approach is often referred to as microdosing. 

Microdosing simply means using very small doses of a medication to achieve therapeutic benefit while minimizing side effects. The concept isn’t new. Physicians frequently adjust medications based on patient sensitivity. For example, antidepressants like escitalopram (Lexapro) are often effective at doses well below the traditional minimum. 

The same principle may apply to semaglutide. In many patients, metabolic and appetite-related effects appear before significant weight loss occurs, suggesting that smaller doses may still influence underlying physiology. 

Some clinicians are also experimenting with alternative dosing schedules, such as extending injections to every two weeks. Preliminary observations suggest these approaches may still maintain much of the drug’s benefit while reducing side effects. 

In our own clinical experience, starting semaglutide at very low doses—sometimes around 20% of the standard starting dose—often results in minimal or no side effects. 

This cautious approach may also reduce potential risks. Rapid dose escalation has been associated with worsening diabetic retinopathy in some patients, likely due to abrupt metabolic changes. 

Microdosing semaglutide is still an evolving area of medicine, and larger studies are needed. But early observations suggest that the anti-inflammatory effects of GLP-1 drugs may not require full weight-loss dosing, opening the door to new therapeutic possibilities. 

Sometimes in medicine, less really may be more. 

For more information on Semaglutide, visit LiquidGoldIVBar.com, or call 781-736-1901 opt. 1.